AbCellera Biologics Inc. (ABCL)
- Previous Close
2.0100 - Open
2.0500 - Bid 1.4700 x 200
- Ask 2.5400 x 200
- Day's Range
1.9850 - 2.0600 - 52 Week Range
1.8910 - 4.3400 - Volume
5,996,522 - Avg. Volume
4,226,604 - Market Cap (intraday)
599.832M - Beta (5Y Monthly) 0.46
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5500 - Earnings Date Aug 4, 2025 - Aug 8, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11.71
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
www.abcellera.comRecent News: ABCL
View More
Performance Overview: ABCL
Trailing total returns as of 5/8/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ABCL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ABCL
View MoreValuation Measures
Market Cap
599.83M
Enterprise Value
39.58M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
20.52
Price/Book (mrq)
0.57
Enterprise Value/Revenue
1.37
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-12.41%
Return on Equity (ttm)
-14.75%
Revenue (ttm)
28.83M
Net Income Avi to Common (ttm)
-162.86M
Diluted EPS (ttm)
-0.5500
Balance Sheet and Cash Flow
Total Cash (mrq)
625.61M
Total Debt/Equity (mrq)
6.19%
Levered Free Cash Flow (ttm)
-177.77M
Research Analysis: ABCL
View MoreResearch Reports: ABCL
View MoreDaily – Vickers Top Buyers & Sellers for 03/12/2025
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 08/30/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 05/30/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 12/21/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.